Fritextsökning
Innehållstyper
-
BMS and venture capital giant form new company
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...
-
Don't miss ZEISS Quality Innovation Days
Digital event April 15-19, 2024.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
Karriärcoachen: Så får du AI att söka jobbet åt dig
För att använda AI effektivt måste vi ändra vårt tankesätt för hur vi kommunicerar. Annars får vi bara döda motivationsbrev och döda resuméer. Det anser karriär...
-
Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy
Understand how RICS can be used to measure diffusion coefficients.
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
JMP Statistical Discovery
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Bico säljer bolag inom in vitro-testning och digital patologi
Bioteknikbolaget Bico avyttrar Mattek och Visikol, som integrerades i Mattek operationellt förra året, till Sartorius Lab. Köpeskillingen är på 80 miljoner doll...
-
De får medicinpriset för upptäckt av immuntolerans
Året Nobelpris i fysiologi eller medicin tilldelas Mary Brunkow, Fred Ramsdell och Shimon Sakaguchi.
-
EXCL Gantry Kit Improve Automated Lab Applications
We’re excited to introduce a new product that improves precision and throughput in life science applications. The EXCL multi-axis gantry kit lowers engineering ...
-
Samuel Lagercrantz: ”Kommer TACO-Trumps tullavtal hålla?”
Olika bud om USA-tullar på läkemedel har skapat osäkerhet. Nu har en överenskommelse slutits, men med Donald Trump som president vet man inte säkert om den komm...
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
How Volume EM Advances Life Science Research
Free webinar series.
-
Medical Plastics Tips & Tricks
Measuringhero video by ZEISS.
-
ZEISS O-INSPECT duo: The multifunctional measuring machine
ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.
-
”Jag vill vara en trädgårdsmästare som får andra att gro”
Vad innebär det att leda Läkemedelsverket? Nytillträdda Ann Lindberg delar med sig av sina tankar om sin första tid på myndigheten och om de frågor som ligger p...
-
Product demo with features, software and best-practices
Get interesting insights about ZEISS O-INSPECT duo in our demo recording.
-
Improve Productivity and Accessibility with Award-winning Human-Centered Design
Enhance your workflow with integrated intelligence.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...
-
“Unfortunately, we are not strong when it comes to conducting clinical trials”
The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.